DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

BACKGROUND: Despite the preclinical promise of CD40 and 4-1BB as immuno-oncology targets, clinical efforts evaluating CD40 and 4-1BB agonists as monotherapy have found limited success. DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and...

Descripción completa

Detalles Bibliográficos
Autores principales: Muik, Alexander, Adams, Homer C, Gieseke, Friederike, Altintas, Isil, Schoedel, Kristina B, Blum, Jordan M, Sänger, Bianca, Burm, Saskia M, Stanganello, Eliana, Verzijl, Dennis, Spires, Vanessa M, Vascotto, Fulvia, Toker, Aras, Quinkhardt, Juliane, Fereshteh, Mark, Diken, Mustafa, Satijn, David P E, Kreiter, Sebastian, Ahmadi, Tahamtan, Breij, Esther C W, Türeci, Özlem, Sasser, Kate, Sahin, Ugur, Jure-Kunkel, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189854/
https://www.ncbi.nlm.nih.gov/pubmed/35688554
http://dx.doi.org/10.1136/jitc-2021-004322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189854/
https://www.ncbi.nlm.nih.gov/pubmed/35688554
http://dx.doi.org/10.1136/jitc-2021-004322

Ejemplares similares